½ÃÀ庸°í¼­
»óǰÄÚµå
1394000

À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå ¿¹Ãø ¹× ºÐ¼®(-2028³â) : Áö¿ªº°, Á¦Ç°º°, ÀýÂ÷º°, ÃÖÁ¾ »ç¿ëÀÚº°

Europe Structural Heart Market Forecast to 2028 - Regional Analysis - by Product, Procedure, and End User

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 146 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå(Structural Heart) ½ÃÀåÀº 2022³â 32¾ï 1,380¸¸ ´Þ·¯¿¡¼­ 2028³â 49¾ï 925¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 2022³âºÎÅÍ 2028³â±îÁöÀÇ CAGRÀº 7.3%·Î ÃßÁ¤µË´Ï´Ù.

Çõ½ÅÀûÀÎ ±¸Á¶Àû ½ÉÀå ¼­ºñ½ºÀÇ °¡¿ë¼ºÀº À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀ» µÞ¹Þħ

±â¼úÀûÀ¸·Î Áøº¸µÈ Á¦Ç°°ú Ä¡·á ¼­ºñ½º¸¦ ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÊ¿¡ µû¶ó ¿Ü°úÀÇ»ç, ÀÇ»ç ¹× ±âŸ ÀÇ·á ¼­ºñ½º Á¦°øÀڴ ȯÀÚ¿¡°Ô ¿ì¼öÇÑ ¼­ºñ½º¸¦ Á¦°øÇÏ¿© ÃÖÀûÀÇ »îÀÇ ÁúÀ» À¯ÁöÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº ÀÇ·á ½Ã¼³¿¡¸¸ ±¹ÇѵÇÁö ¾Ê°í ȯÀÚ°¡ Ä¡·á ½Ã¼³¿¡¼­ ÇýÅÃÀ» ¹ÞÀ» ¼ö ÀÖµµ·Ï ¼³°èµÈ ÇÁ·Î±×·¥À¸·Î È®ÀåµÇ°í ÀÖ½À´Ï´Ù. ½ÉÀå ÁúȯÀº º¹ÀâÇϱ⠶§¹®¿¡ Ä¡·áÀÇ ¼º°ø ¿©ºÎ´Â ÀÌÀü¿¡´Â ºÒ°¡´ÉÇÏ´Ù°í ¿©°ÜÁ³´ø Ä¡·á ¿É¼ÇÀ» Çö½Ç·Î ¸¸µå´Â Çõ½Å¿¡ ´Þ·Á ÀÖ½À´Ï´Ù. ±¸Á¶Àû ¹ß¸íǰºÎÅÍ ¼ö¼úÀû ÆÇ¸· ¿ä¹ý¿¡ À̸£±â±îÁö ½ÉÀå Áúȯ Ä¡·á ȯ°æÀº Áö³­ ¼ö½Ê ³â µ¿¾È ȹ±âÀûÀÎ Çõ½ÅÀ» °æÇèÇØ ¿Ô½À´Ï´Ù. ±¸Á¶Àû ½ÉÀå ½ÃÀåÀÇ ±â¾÷µéÀº Ç÷°ü Áúȯ, ºÒ±ÔÄ¢ÇÑ ½ÉÀå ¹Úµ¿, ½ÉÀå ÆÇ¸· Áúȯ µî ´Ù¾çÇÑ ½ÉÀå Áúȯ¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ ¼Ö·ç¼Ç Æ÷Æ®Æú¸®¿À¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌÁ¦ ÀÇ»ç´Â ¿ø°Ý ¸ð´ÏÅ͸µ ÀåÄ¡¸¦ »ç¿ëÇÏ¿© ȯÀÚ¸¦ Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÔÀ¸·Î½á ºÎÁ¤¸ÆÀ» °ü¸®ÇÏ°í ´Ù¾çÇÑ ±¸Á¶Àû ½ÉÀå ÁúȯÀ» Ä¡·áÇÒ ¼ö ÀÖ½À´Ï´Ù.

¹Ì±¹ ½ÄǰÀǾ౹(FDA)Àº ƯÁ¤ ȯÀÚ±ºÀ¸·Î Á¦ÇѵǴ ´Ù¾çÇÑ Ä¡·á¹ýÀ» ½ÂÀÎÇß½À´Ï´Ù. ¿¹¸¦ µé¾î, Çõ½ÅÀûÀÎ ½ÉÀå ±¸Á¶ ¼­ºñ½º Á¦°ø¾÷ü Áß ÇϳªÀÎ ÇÁ¸®¹Ì¾î Çコ´Â ºñÈļº ½É±ÙÁõ¿¡ ´ëÇÑ ¾ËÄÚ¿Ã Áß°Ý ÀýÁ¦¼ú Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ Ä¡·á´Â ÁÖ·Î Ä«Å×ÅÍ ±â¹Ý ±â¼úÀ» »ç¿ëÇÕ´Ï´Ù. µüµüÇϰí Á¼Àº ½ÉÀå ÆÇ¸·À» ³ÐÇôÁִ dz¼± ÆÇ¸· ¼ºÇü¼ú, ¼ö¼ú ¾øÀÌ ½ÉÀåÀÇ Á½ɹæ°ú ¿ì½É¹æ »çÀÌÀÇ ±¸¸ÛÀ» ¸·´Â ½É¹æÁ߰ݰá¼Õ °æÇÇÀû Ä¡·á µî ´Ù¾çÇÑ ¼­ºñ½º¸¦ Á¦°øÇϰí ÀÖ´Ù. ¼¾Æ®¶óÄɾîÀÇ ½ÉÀå ¹× Ç÷°ü ¼¾ÅÍ´Â ¿¡ÄÚÇȼ¿ÀÇ True3D ¹× HTG »çÀü °èȹ ¼ÒÇÁÆ®¿þ¾î¸¦ »ç¿ëÇߴµ¥, ÀÌ ¼ÒÇÁÆ®¿þ¾î´Â È¥ÇÕ Çö½Ç ±â´ÉÀ» Á¦°øÇÏ¿© ±¸Á¶Àû ½ÉÀå Ä¡·áÆÀÀÌ È¯ÀÚÀÇ ÇØºÎÇÐÀû ±¸Á¶¸¦ ¹°¸®ÀûÀ¸·Î ¸¸Áö°Å³ª Á¶¿µÁ¦ ¹× ¹æ»ç¼±¿¡ ³ëÃâÇÏÁö ¾Ê°íµµ ½Ç½Ã°£ Ȧ·Î±×·¥ ¹öÀü°ú »óÈ£ÀÛ¿ëÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù.

±¸Á¶Àû ½ÉÀå ÇÁ·Î±×·¥ÀÇ Çõ½ÅÀûÀÎ ±â¼ú°ú ±â¼úÀº ȯÀÚ¿¡°Ô ÃÖ»óÀÇ °á°ú¸¦ Á¦°øÇÏ´Â °íǰÁú Ä¡·á¸¦ Á¦°øÇϱâ À§ÇØ Æ¯º°È÷ ¼³°èµÇ¾úÀ¸¸ç ÇÕº´ÁõÀÌ Àû°í ȸº¹¿¡ ¼Ò¿äµÇ´Â ½Ã°£ÀÌ Âª°í ¿À·¡ Áö¼ÓµË´Ï´Ù. ÀåÁ¡ÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ±¸Á¶Àû ½ÉÀå ÁúȯÀ¸·Î °íÅë¹Þ´Â ȯÀÚ¸¦ ´õ ¸¹ÀÌ ²ø¾îµéÀÏ °¡´É¼ºÀÌ ³ôÀ¸¸ç, °á±¹ ¼­ºñ½ºÀÇ ÀÌÁ¡ÀÌ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» Áõ°¡½Ãų °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå °³¿ä

À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀº µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ ¹× ±âŸ À¯·´À¸·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áö¿ªÀº ±¸Á¶Àû ½ÉÀå ½ÃÀå¿¡¼­ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀº °í·ÉÀÚ Àα¸ÀÇ ´ëÆøÀûÀÎ Áõ°¡, CVD ÀÌȯÀ²ÀÇ »ó½Â, µ¿Áö¿ª ½ÃÀå ÁøÃâ±â¾÷¿¡ ÀÇÇÑ Çõ½ÅÀû Á¦Ç°ÀÇ ¹ß¸Å µîÀÇ ¿äÀο¡ ÀÇÇØ ¿¹Ãø ±â°£Áß¿¡ ´ëÆøÀûÀÎ ¼ºÀåÀÌ Àü¸ÁµÇ°í ÀÖ´Ù ÇÕ´Ï´Ù. ¶ÇÇÑ À¯·´¿¡¼­´Â ½ÉÀ庴 Ä¡·áÁ¦ÀÇ ½ÂÀÎ ¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÃÀå °¢»ç´Â ´õ ¸¹Àº °í°´ÃþÀ» ȹµæÇÏ°í ½ÃÀå °æÀï·ÂÀ» À¯ÁöÇϱâ À§ÇØ ´Ù¾çÇÑ ³ë·ÂÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸ðµç ¿äÀεéÀº ÀÌ Áö¿ª ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

2028³â±îÁö À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå ¼öÀÍ ¹× ¿¹Ãø(±Ý¾×)

À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀÇ ¼¼ºÐÈ­

À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀº Á¦Ç°, ÀýÂ÷, ÃÖÁ¾ »ç¿ëÀÚ, ±¹°¡º°·Î ±¸ºÐµË´Ï´Ù.

Á¦Ç°º°·Î À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀº Æó»ö±â, ȯÇü ¼ºÇü ¸µ, ½ÉÀå ÆÇ¸· dz¼± µîÀ¸·Î ±¸ºÐµË´Ï´Ù. Æó»ö±â ºÎ¹®Àº 2022³â À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

ÀýÂ÷º°·Î º¼ ¶§, À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀº ½ÉÀå ÆÇ¸· ÇùÂøÁõ, ½ÉÀå ÆÇ¸· ¿ª·ùÁõ, ÁÂ½É¹æ ºÎ¼Ó±â Æó¼â ºÎÀüÁõÀ¸·Î ±¸ºÐµË´Ï´Ù. ½ÉÀå ÆÇ¸· ÇùÂøÁõ ºÎ¹®Àº 2022³â À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚ¸¦ ±â¹ÝÀ¸·Î À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀº º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) ¹× ½ÉÀå ¼¾ÅÍ·Î ±¸ºÐµË´Ï´Ù. º´¿ø ºÎ¹®Àº 2022³â À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀº µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ ¹× ±âŸ À¯·´À¸·Î ±¸ºÐµË´Ï´Ù. 2022³â À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀº µ¶ÀÏÀÌ µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.

Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, Artivion Inc, Edwards Lifesciences Corp, Lepu Medical Technology Beijing Co Ltd, Braile Biomedical Industry, Commerce and Representations, Micro Interventional Devices Inc µîÀº À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå¿¡¼­ »ç¾÷À» ´ë±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå-ÁÖ¿ä Æ÷ÀÎÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå-½ÃÀå »óȲ

  • °³¿ä
  • PEST ºÐ¼®
    • À¯·´ÀÇ PEST ºÐ¼®
  • Àü¹®°¡ÀÇ °ßÇØ

Á¦5Àå À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø ¿äÀÎ
    • Çõ½ÅÀûÀÎ ±¸Á¶Àû ½ÉÀå ¼­ºñ½ºÀÇ °¡¿ë¼º
    • ½ÉÇ÷°ü Áúȯ Áõ·Ê Áõ°¡¿Í Æ®·¹ÀÌ´× ÇÁ·Î±×·¥
  • ÁÖ¿ä ½ÃÀå ¼ºÀå ¾ïÁ¦ ¿äÀÎ
    • ¼ö¼ú ºñ¿ëÀÇ ³ôÀÌ
    • ±¸Á¶Àû ½ÉÀå ÀåÄ¡¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦
  • ÁÖ¿ä ½ÃÀå ±âȸ
    • ±¸Á¶Àû ½ÉÀå¿¡¼­ ÀΰøÁö´ÉÀÇ ÀÌ¿ë È®´ë
  • ÇâÈÄ µ¿Çâ
    • ±¸Á¶Àû ½ÉÀå µð¹ÙÀ̽º ºÐ¾ß¿¡¼­ ±â¼úÀÇ Áøº¸
  • ¿µÇ⠺м®

Á¦6Àå À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå-À¯·´ ºÐ¼®

  • À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀÇ ¼öÀÍ ¿¹Ãø ¹× ºÐ¼®

Á¦7Àå À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå ¼öÀÍ ¹× ¿¹Ãø(-2028³â) : Á¦Ç°º°

  • À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå : Á¦Ç°º°, ¼öÀÍ Á¡À¯À²(2021³â, 2028³â)
  • Æó»ö±â
  • ȯ»ó ¼ºÇü ¸µ
  • ½ÉÀåÆÇ dz¼±
  • ±âŸ

Á¦8Àå À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå ¼öÀÍ ¹× ¿¹Ãø(-2028³â) : ÀýÂ÷º°

  • À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå : ÀýÂ÷º°, ¼öÀÍ Á¡À¯À²(2021³â, 2028³â)
  • ½ÉÀåÆÇ ÇùÂøÁõ
  • ½ÉÀå ÆÇ¸· ¿ª·ù
  • ÁÂ½É¹æ ºÎ¼Ó±â Æó¼â ºÎÀüÁõ

Á¦9Àå À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå ¼öÀÍ ¹× ¿¹Ãø(-2028³â) : ÃÖÁ¾ »ç¿ëÀÚº°

  • À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°, ¼öÀÍ Á¡À¯À²(2021³â, 2028³â)
  • º´¿ø
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ½ÉÀå¼¾ÅÍ

Á¦10Àå À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå ¼öÀÍ ¹× ¿¹Ãø(-2028³â) : ±¹°¡º° ºÐ¼®

Á¦11Àå À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå-¾÷°è »óȲ

  • ¼ºÀå Àü·«

Á¦12Àå À¯·´ÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå ±â¾÷ °³¿ä

  • Abbott Laboratories
  • Medtronic Plc
  • Boston Scientific Corp
  • Artivion Inc
  • Edwards Lifesciences Corp
  • Lepu Medical Technology Beijing Co Ltd
  • Aran Biomedical Teoranta
  • Corcym UK Ltd

Á¦13Àå ºÎ·Ï

LYJ 23.12.15

The Europe structural heart market is expected to grow from US$ 3,213.80 million in 2022 to US$ 4,909.25 million by 2028. It is estimated to grow at a CAGR of 7.3% from 2022 to 2028.

Availability of Innovative Structural Heart Services Fuel Europe Structural Heart Market

The availability of technologically advanced products and treatment services allows surgeons, physicians, and other healthcare providers to offer superior services to their patients, which helps them maintain the optimum quality of life. The innovations are not limited to healthcare facilities, and they are extended to programs that are being designed for patients to get benefits out of treatment facilities. Heart diseases are complex, and the success of their intervention depends on innovations bringing treatment options that were deemed impossible earlier into reality. The heart disease treatment landscape-from structural inventions to surgical valve therapies-has experienced breakthrough innovations over the past few decades. Companies in the structural heart market offer a broad portfolio of solutions for different heart conditions, including vascular disease, irregular heartbeats, and heart valve diseases. Physicians can now manage arrhythmias by using remote monitoring devices to keep a tab on their patients, thereby treating an array of structural heart conditions.

The food and Drug Administration (FDA) have approved various therapies that are limited to the selected groups the patients. For instance, Premier Health, one of the providers of innovative structural heart services, offers alcohol septal ablation treatment for hypertrophic cardiomyopathy. The treatment mainly uses a catheter-based technology. The balloon valvuloplasty, uses a transcatheter approach for widening up stiff and narrow heart valves, atrial septal defect transcatheter repair which closes an opening between the heart's left and right atrium without surgery and such more services are being provided by the service providers. CentraCare's Heart & Vascular Center used EchoPixel's True3D and HTG pre-planning software, which provides mixed reality capabilities that allow structural heart care teams to interact with a real-time holographic version of the patient's anatomy without physically touching it or exposing it to contrast agents and radiations.

The innovative technologies and techniques of structural heart programs are specifically designed to provide quality care for the best results for patients and provides less complications and shorter recovery times with long-lasting advantages. Such technologies are likely to attract more patients suffering from the structural heart diseases and eventually the benefits of the services are likely to enhance the growth of the market in the forecasted period.

Europe Structural Heart Market Overview

The European structural heart market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant market share in the structural heart market. The European structural heart market is expected to witness significant growth during the forecast period due to factors such as significant growth in elderly population, rise in the incidence of CVDs, and launch of innovative products by market players in the region. Also, there has been an increase in the number of product approvals for treating heart disease in Europe. Moreover, market players have undertaken a number of initiatives to attract a larger customer base and sustain the competitive nature of the market. All these factors are fueling the market growth in the region.

Europe Structural Heart Market Revenue and Forecast to 2028 (US$ Million)

Europe Structural Heart Market Segmentation

The Europe structural heart market is segmented int product, procedure, end user, and country.

Based on product, the Europe structural heart market is segmented into occluders, annuloplasty rings, heart valve balloons, and others. The occluders segment held the largest share of the Europe structural heart market in 2022.

Based on procedure, the Europe structural heart market is segmented into heart valve stenosis, heart valve regurgitation, and left atrial appendage closure. The heart valve stenosis segment held the largest share of the Europe structural heart market in 2022.

Based on end user, the Europe structural heart market is segmented into hospitals, ambulatory surgical centers, and cardiac centers. The hospitals segment held the largest share of the Europe structural heart market in 2022.

Based on country, the Europe structural heart market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe structural heart market in 2022.

Abbott Laboratories; Medtronic Plc; Boston Scientific Corp; Artivion Inc; Edwards Lifesciences Corp; Lepu Medical Technology Beijing Co Ltd; Braile Biomedical Industry, Commerce and Representations; and Micro Interventional Devices Inc are some of the leading companies operating in the Europe structural heart market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe structural heart market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in Europe structural heart market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Europe Structural Heart Market - by Product
    • 1.3.2 Europe Structural Heart Market - by Procedure
    • 1.3.3 Europe Structural Heart Market - by End User
    • 1.3.4 Europe Structural Heart Market - by Country

2. Europe Structural Heart Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Structural Heart Market - Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 Europe PEST Analysis
  • 4.3 Expert's Opinion

5. Europe Structural Heart Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Availability of Innovative Structural Heart Services
    • 5.1.2 Rising Number of Cardiovascular Disease Cases and Training Programs
  • 5.2 Key Market Restraints
    • 5.2.1 High Cost of Procedures
    • 5.2.2 Stringent Regulations Regarding Structure Heart Devices
  • 5.3 Key Market Opportunities
    • 5.3.1 Growing Use of Artificial Intelligence in Structural Heart
  • 5.4 Future Trends
    • 5.4.1 Technological Advancements in the Field of Structural Heart Devices
  • 5.5 Impact analysis

6. Europe Structural Heart Market -Europe Analysis

  • 6.1 Europe Structural Heart Market Revenue Forecast and Analysis

7. Europe Structural Heart Market - Revenue and Forecast to 2028 - by Product

  • 7.1 Overview
  • 7.2 Europe Structural Heart Market Revenue Share, by Product 2021 & 2028 (%)
  • 7.3 Occluders
    • 7.3.1 Overview
    • 7.3.2 Occluders: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Annuloplasty Rings
    • 7.4.1 Overview
    • 7.4.2 Annuloplasty Rings: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.5 Heart Valve Balloons
    • 7.5.1 Overview
    • 7.5.2 Heart Valve Balloons: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)

8. Europe Structural Heart Market - Revenue and Forecast to 2028 - by Procedure

  • 8.1 Overview
  • 8.2 Europe Structural Heart Market Revenue Share, by Procedure 2021 & 2028 (%)
  • 8.3 Heart Valve Stenosis
    • 8.3.1 Overview
    • 8.3.2 Heart Valve Stenosis: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.4 Heart Valve Regurgitation
    • 8.4.1 Overview
    • 8.4.2 Heart Valve Regurgitation: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.5 Left Atrial Appendage Closure
    • 8.5.1 Overview
    • 8.5.2 Left Atrial Appendage Closure: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)

9. Europe Structural Heart Market - Revenue and Forecast to 2028 - by End User

  • 9.1 Overview
  • 9.2 Europe Structural Heart Market Revenue Share, by End User 2021 & 2028 (%)
  • 9.3 Hospitals
    • 9.3.1 Overview
    • 9.3.2 Hospitals: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.4 Ambulatory Surgical Centers
    • 9.4.1 Overview
    • 9.4.2 Ambulatory Surgical Centers: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.5 Cardiac Centers
    • 9.5.1 Overview
    • 9.5.2 Cardiac Centers: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)

10. Europe Structural Heart Market - Revenue and Forecast to 2028 -Country Analysis

  • 10.1 Overview
    • 10.1.1 Europe Structural Heart Market, by Country, 2021 & 2028 (%)
      • 10.1.1.1 Germany: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.1.1 Overview
        • 10.1.1.1.2 Germany: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.1.3 Germany: Europe Structural Heart Market, by Product, 2019-2028 (US$ Million)
        • 10.1.1.1.4 Germany: Europe Structural Heart Market, by Procedure, 2019-2028 (US$ Million)
        • 10.1.1.1.4.1 Germany: Europe Structural Heart Market, by Heart Valve Stenosis Procedure, 2019-2028 (US$ Million)
        • 10.1.1.1.4.2 Germany: Europe Structural Heart Market, by Heart Valve Regurgitation Procedure, 2019-2028 (US$ Million)
        • 10.1.1.1.5 Germany: Europe Structural Heart Market, by End User, 2019-2028 (US$ Million)
      • 10.1.1.2 UK: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.2.1 Overview
        • 10.1.1.2.2 UK: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.2.3 UK: Europe Structural Heart Market, by Product, 2019-2028 (US$ Million)
        • 10.1.1.2.4 UK: Europe Structural Heart Market, by Procedure, 2019-2028 (US$ Million)
        • 10.1.1.2.4.1 UK: Europe Structural Heart Market, by Heart Valve Stenosis Procedure, 2019-2028 (US$ Million)
        • 10.1.1.2.4.2 UK: Europe Structural Heart Market, by Heart Valve Regurgitation Procedure, 2019-2028 (US$ Million)
        • 10.1.1.2.5 UK: Europe Structural Heart Market, by End User, 2019-2028 (US$ Million)
      • 10.1.1.3 France: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.3.1 Overview
        • 10.1.1.3.2 France: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.3.3 France: Europe Structural Heart Market, by Product, 2019-2028 (US$ Million)
        • 10.1.1.3.4 France: Europe Structural Heart Market, by Procedure, 2019-2028 (US$ Million)
        • 10.1.1.3.4.1 France: Europe Structural Heart Market, by Heart Valve Stenosis Procedure, 2019-2028 (US$ Million)
        • 10.1.1.3.4.2 France: Europe Structural Heart Market, by Heart Valve Regurgitation Procedure, 2019-2028 (US$ Million)
        • 10.1.1.3.5 France: Europe Structural Heart Market, by End User, 2019-2028 (US$ Million)
      • 10.1.1.4 Italy: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.4.1 Overview
        • 10.1.1.4.2 Italy: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.4.3 Italy: Europe Structural Heart Market, by Product, 2019-2028 (US$ Million)
        • 10.1.1.4.4 Italy: Europe Structural Heart Market, by Procedure, 2019-2028 (US$ Million)
        • 10.1.1.4.4.1 Italy: Europe Structural Heart Market, by Heart Valve Stenosis Procedure, 2019-2028 (US$ Million)
        • 10.1.1.4.4.2 Italy: Europe Structural Heart Market, by Heart Valve Regurgitation Procedure, 2019-2028 (US$ Million)
        • 10.1.1.4.5 Italy: Europe Structural Heart Market, by End User, 2019-2028 (US$ Million)
      • 10.1.1.5 Spain: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.5.1 Overview
        • 10.1.1.5.2 Spain: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.5.3 Spain: Europe Structural Heart Market, by Product, 2019-2028 (US$ Million)
        • 10.1.1.5.4 Spain: Europe Structural Heart Market, by Procedure, 2019-2028 (US$ Million)
        • 10.1.1.5.4.1 Spain: Europe Structural Heart Market, by Heart Valve Stenosis Procedure, 2019-2028 (US$ Million)
        • 10.1.1.5.4.2 Spain: Europe Structural Heart Market, by Heart Valve Regurgitation Procedure, 2019-2028 (US$ Million)
        • 10.1.1.5.5 Spain: Europe Structural Heart Market, by End User, 2019-2028 (US$ Million)
      • 10.1.1.6 Rest of Europe: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.6.1 Overview
        • 10.1.1.6.2 Rest of Europe: Europe Structural Heart Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.6.3 Rest of Europe: Europe Structural Heart Market, by Product, 2019-2028 (US$ Million)
        • 10.1.1.6.4 Rest of Europe: Europe Structural Heart Market, by Procedure, 2019-2028 (US$ Million)
        • 10.1.1.6.4.1 Rest of Europe: Europe Structural Heart Market, by Heart Valve Stenosis Procedure, 2019-2028 (US$ Million)
        • 10.1.1.6.4.2 Rest of Europe: Europe Structural Heart Market, by Heart Valve Regurgitation Procedure, 2019-2028 (US$ Million)
        • 10.1.1.6.5 Rest of Europe: Europe Structural Heart Market, by End User, 2019-2028 (US$ Million)

11. Europe Structural Heart Market-Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies
    • 11.2.1 Overview

12. Company Profiles

  • 12.1 Abbott Laboratories
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Medtronic Plc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Boston Scientific Corp
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Artivion Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Edwards Lifesciences Corp
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Lepu Medical Technology Beijing Co Ltd
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Aran Biomedical Teoranta
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Corcym UK Ltd
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments

13. Appendix

  • 13.1 About the Insight Partners
  • 13.2 Glossary of Terms
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦